Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review

Sroka, Natalia; Rydzewska–Rosołowska, Alicja; Kakareko, Katarzyna; Rosołowski, Mariusz; Głowińska, Irena; Hryszko, Tomasz

doi:10.3390/nu15010090

Cited by 19 publications

(20 citation statements)

References 200 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, due to the invasiveness of the test, breath tests (BTs) with glucose (GBT) or lactulose (LBT) are more commonly used. A concentration of ≥10 3 CFU/mL in a culture or an increase of ≥20 ppm in the concentration of hydrogen compared to baseline is synonymous with a SIBO diagnosis [ 36 , 37 , 38 , 39 ].…”

Section: Small Intestinal Bacterial Overgrowth—sibomentioning

confidence: 99%

“…Numerous studies describe the simultaneous occurrence of SIBO and IBS (irritable bowel syndrome) [ 40 , 41 , 42 , 43 ]. Both disorders stimulate the immune system, which increases pro-inflammatory cytokines in the intestinal mucosa and may increase its permeability [ 36 ]. Research also indicates that bacterial overgrowth is more common for people suffering from IBS-C (Irritable Bowel Syndrome with Constipation) than for those suffering from IBS-D (Irritable Bowel Syndrome with Diarrhoea) [ 44 ].…”

Section: Small Intestinal Bacterial Overgrowth—sibomentioning

confidence: 99%

“…A wide range of research papers confirms the multifactorial impact of SIBO on gastrointestinal, cardiovascular, endocrine, neurological, nephrological and bone diseases. Despite this, more research is still needed to identify effective treatments and prevent small intestinal bacterial overgrowth [ 36 ].…”

Section: Small Intestinal Bacterial Overgrowth—sibomentioning

confidence: 99%

See 2 more Smart Citations

Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

et al. 2023

View full text Add to dashboard Cite

Gut microbiota is the aggregate of all microorganisms in the human digestive system. There are 1014 CFU/mL of such microorganisms in the human body, including bacteria, viruses, fungi, archaea and protozoa. The Firmicutes and Bacteroidetes bacteria phyla comprise 90% of the human gut microbiota. The microbiota support the healthy functioning of the human body by helping with digestion (mainly via short-chain fatty acids and amino acids) and producing short-chain fatty acids. In addition, it exhibits many physiological functions, such as forming the intestinal epithelium, intestinal integrity maintenance, the production of vitamins, and protection against pathogens. An altered composition or the number of microorganisms, known as dysbiosis, disrupts the body’s homeostasis and can lead to the development of inflammatory bowel disease, irritable bowel syndrome, and metabolic diseases such as diabetes, obesity and allergies. Several types of disruptions to the gut microbiota have been identified: SIBO (Small Intestinal Bacterial Overgrowth), LIBO (Large Intestinal Bacterial Overgrowth), SIFO (Small Intestinal Fungal Overgrowth), and IMO (Intestinal Methanogen Overgrowth). General gastrointestinal problems such as abdominal pain, bloating, gas, diarrhoea and constipation are the main symptoms of dysbiosis. They lead to malabsorption, nutrient deficiencies, anaemia and hypoproteinaemia. Increased lipopolysaccharide (LPS) permeability, stimulating the inflammatory response and resulting in chronic inflammation, has been identified as the leading cause of microbial overgrowth in the gut. The subject literature is extensive but of limited quality. Despite the recent interest in the gut microbiome and its disorders, more clinical research is needed to determine the pathophysiology, effective treatments, and prevention of small and large intestinal microbiota overgrowth. This review was designed to provide an overview of the available literature on intestinal microbial dysbiosis (SIBO, LIBO, SIFO and IMO) and to determine whether it represents a real threat to human health.

show abstract

Section: Small Intestinal Bacterial Overgrowth—sibomentioning

confidence: 99%

Section: Small Intestinal Bacterial Overgrowth—sibomentioning

confidence: 99%

See 1 more Smart Citation

Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Fizjologicznie okolica ta jest uboga w bakterie. [2] SIBO polega nie tylko na zmianie ilościowej, ale również jakościowej składu mikrobioty jelita cienkiego, dlatego też wśród gatunków związanych z zaburzeniem pojawiają się zarówno bakterie Gramdodatnie i Gram-ujemne, ale również beztlenowe, charakterystyczne dla jelita grubego. Wśród nich należy wymienić Streptococcus, Staphylococcus, Bacteroides, Lactobacillus i Enterobacteriaceae -Escherichia, Klebsiella lub Proteus [2,33] Objawy Dolegliwości u pacjentów mogą być niecharakterystyczne.…”

Section: Zarys Problemuunclassified

“…[2] SIBO polega nie tylko na zmianie ilościowej, ale również jakościowej składu mikrobioty jelita cienkiego, dlatego też wśród gatunków związanych z zaburzeniem pojawiają się zarówno bakterie Gramdodatnie i Gram-ujemne, ale również beztlenowe, charakterystyczne dla jelita grubego. Wśród nich należy wymienić Streptococcus, Staphylococcus, Bacteroides, Lactobacillus i Enterobacteriaceae -Escherichia, Klebsiella lub Proteus [2,33] Objawy Dolegliwości u pacjentów mogą być niecharakterystyczne. Zalicza się do nich zaburzenia żołądkowo-jelitowe, manifestujące się jako bóle brzucha, nudności, wzdęcia, dyskomfort , biegunki, zaparcia, ponadto zmniejszenie masy ciała, niedobory pokarmowe .…”

Section: Zarys Problemuunclassified

SIBO - the present knowledge within the contekst of clinical dependencies and therapy

Marta

LESZCZ²,

BIEŃKO

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: The gut microbiome is an integral part of the body, and the eubiosis conditio significantly influences homeostasis. Small intestinal bacterial overgrowth (SIBO) is connected with an increased numer of bacteria, it causes gastrointestinal symptoms. The main symptoms are abdominal pain, bloating and diarrhea. SIBO correlates with the occurrence of other chronic diseases. The basis of treatment are antibiotics. There are also scientific reports on supplementing pharmacological therapy with dietary management. Objective: The purpose of this paper is to review the current knowledge on the bacterial overgrowth of the small intestine. Particular attention took notice of to the relationship between SIBO and other chronic diseases as well as potential and applied treatments. Material and methods: The review includes publications published in 2020-2023 and certain works published earlier, in the years 2008-2017. Data were collected using PubMed, ScienceDirect i Google Scholar. Results: Small intestinal bacterial overgrowth is heterogeneous disorder. Its symptoms are nonspecific. SIBO is related to several different diseases and corresponds with them. Empirical treatment consists in administration of antibiotics. Supplementing therapy with alternative methods for example probiotic and diet therapy promotes success in treating. Conclusions: The lack of standarized therapeutic menagment and focused on bacterial eradication only approach makes, SIBO is recurrent ailment. More research is needed. The important thing is holistic approach on etiology, pathogenesis and therapy.

show abstract

Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms

Romano,

Napolitano,

Crocetto

et al. 2024

The Prostate

View full text Add to dashboard Cite

BackgroundGut microbiome is a community of microorganisms that lives in the human intestine and exerts various functions on the host, including metabolic, immunoregulatory, and control over cell proliferation. Gut microbiome alterations have been associated with various pathological conditions, such as diabetes mellitus, obesity, and cardiovascular diseases. Gut‐prostate axis is explained by the association between gut microbiome quantitative and functional alterations along with increased intestinal epithelial permeability with prostatediseases. However, the pathophysiological mechanisms and clinical importance of this association are not completely clarified yet.MethodsWe conducted a narrative review of the most relevant articles in the Medline (US National Library of Medicine, Bethesda, MD, USA), Scopus (Elsevier, Amsterdam, The Netherlands) and Web of Science Core Collection (Thomson Reuters, Toronto, ON, Canada) databases. No chronological restrictions were applied, and the most related papers published until December 2023 were included.ResultsGut microbiota (GM) and its metabolites are capable of modifying host androgen level, as well as prostate cancer (PCa) therapy response. Moreover, patients with inflammatory bowel disease have higher rates of prostatitis‐like symptoms and a potential risk of developing PCa.ConclusionsThere is evidence that interventions on the GM and its metabolites have a high potential to serve as diagnostic and therapeutic tools for prostate diseases, including PCa.

show abstract

Show Me What You Have Inside—The Complex Interplay between SIBO and Multiple Medical Conditions—A Systematic Review

Cited by 19 publications

References 200 publications

Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

Association between Gut Dysbiosis and the Occurrence of SIBO, LIBO, SIFO and IMO

SIBO - the present knowledge within the contekst of clinical dependencies and therapy

Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms

Contact Info

Product

Resources

About